Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine

Cancer

Volumn 103, Issue 5, 2005, Pages 994-999

  Numico, Gianmauro ^a   Garrone, Ornella ^a   Dongiovanni, Vincenzo ^b   Silvestris, Nicola ^c   Colantonio, Ida ^a   Di Costanzo, Gianna ^a   Granetto, Cristina ^a   Occelli, Marcella ^a   Fea, Elena ^a   Heouaine, Abdelamid ^a   Gasco, Milena ^a   Merlano, Marco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c SANTA MARIA GORETTI HOSPITAL   (Italy)

Author keywords

Chemotherapy; Cisplatin; Nonsmall cell lung carcinoma; Vascular events

Indexed keywords

CISPLATIN; DEXAMETHASONE; ERYTHROPOIETIN; GEMCITABINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; METOCLOPRAMIDE;

ADRENAL METASTASIS; ADULT; AGED; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LEG THROMBOSIS; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; RISK FACTOR; VASCULAR DISEASE; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; EMBOLISM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOSIS; TIME FACTORS;

EID: 13944267884     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20893     Document Type: Article

References (23)

1. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003; 349:109-111.
2. Otten HM, Mathijssen J, ten Gate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med. 2004;164:190-194.
3. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-294.
4. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4:1405-1417.
5. Licciarello JT, Moake JL, Rudi CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985;42:296-300.
6. Talcott JA, Herman TS. Acute ischemic vascular events and cisplatin. Ann Intern Med. 1987;107:121-122.
7. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancer associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
8. Ginsberg JS. Management of venous thromboembolism. N Engl J Med. 1996;335:1816-1828.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20: 4285-4291.
10. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12-18.
11. Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999; 17:3522-3530.
12. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122-130.
13. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000;18:1451-1457.
14. Smit EF, van Meerbeeck J, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol. 2003;21:3909-3917.
15. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
16. Caine GJ, Stonelake PS, Rea D, Lip GYH. Coagulopathic complications in breast cancer. Cancer. 2003;98:1578-1586.
17. Levine MN, Gent M, Hirsh J. The thrombogenic effect of anticancer drug therapy in women with Stage II breast cancer. N Engl J Med. 1988;318:404-407.
18. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in Stage IV breast cancer treated with a five-drug chemotherapy regimen. Cancer. 1984;54:1264-1268.
19. Weijl NI, Rutten MFJ, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169-2178.
20. Czaykowski PM, Moore MJ, Tannok IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160: 2021-2024.
21. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer. 1997;33:1592-1596.
22. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer. 1991;68:2621-2624.
23. Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987;5:1998-2003.